Coya Therapeutics Inc (COYA)

Feb 25, 2025

Can GLP-1 Agonists Transform Alzheimer's Treatment? Coya Therapeutics Experts Weigh In - StockTitan

Feb 25, 2025

Feb 22, 2025

Coya reports promising Alzheimer's treatment study results - MSN

Feb 22, 2025

Feb 20, 2025

Long Term Trading Analysis for (COYA) - Stock Traders Daily

Feb 20, 2025

Feb 20, 2025

Robust Growth in AI in Clinical Trials Market (2025-2032): - openPR

Feb 20, 2025

Feb 14, 2025

Newbridge Financial Services Group Inc. Makes New Investment in Coya Therapeutics, Inc. (NASDAQ:COYA) - MarketBeat

Feb 14, 2025

Feb 10, 2025

Coya Therapeutics (NASDAQ:COYA) Earns "Buy" Rating from D. Boral Capital - MarketBeat

Feb 10, 2025

Feb 10, 2025

Coya Therapeutics (NASDAQ:COYA) Receives Buy Rating from Chardan Capital - MarketBeat

Feb 10, 2025

Feb 10, 2025

(COYA) Trading Advice - Stock Traders Daily

Feb 10, 2025

Feb 09, 2025

BTIG maintains Coya Therapeutics stock buy rating, $15 target - MSN

Feb 09, 2025

Feb 07, 2025

Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD (NASDAQ:COYA) - Seeking Alpha

Feb 07, 2025

Feb 07, 2025

Coya: A Few Catalysts On The Way For COYA-302 Makes This A Must Watch - Seeking Alpha

Feb 07, 2025

Feb 07, 2025

Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's disease - Marketscreener.com

Feb 07, 2025

Feb 07, 2025

Coya Therapeutics Inc (COYA) Shares Rise Despite Market Challenges - The News Heater

Feb 07, 2025

Feb 07, 2025

Coya reports promising Alzheimer’s treatment study results By Investing.com - Investing.com Nigeria

Feb 07, 2025

Feb 06, 2025

Coya: Low-Dose IL-2 in AD patients resulted in reduced proinflammatory markers - TipRanks

Feb 06, 2025

Feb 06, 2025

Coya Therapeutics, Inc. Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development - Marketscreener.com

Feb 06, 2025

Feb 06, 2025

Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing - AOL

Feb 06, 2025

Feb 06, 2025

Why Is Coya Therapeutics Stock Trading Higher Today?Coya Therapeutics (NASDAQ:COYA) - Benzinga

Feb 06, 2025

Feb 06, 2025

Coya Therapeutics Inc Reports Significant Improvement In Inflammatory Markers In Alzheimer's Patients - Marketscreener.com

Feb 06, 2025

Feb 06, 2025

Coya reports promising Alzheimer's treatment study results By Investing.com - Investing.com UK

Feb 06, 2025

Feb 06, 2025

Breakthrough: Alzheimer's Drug Delivers 4.93-Point Memory Score Gain in Clinical Trial - StockTitan

Feb 06, 2025

Feb 04, 2025

Coya Therapeutics CEO to Showcase Novel T Cell Platform at Major Healthcare Conference - StockTitan

Feb 04, 2025

Jan 29, 2025

(COYA) Long Term Investment Analysis - Stock Traders Daily

Jan 29, 2025

Jan 27, 2025

An ALS treatment wave is approaching, and this biotech CEO is ready to surf - PharmaVoice

Jan 27, 2025

Jan 22, 2025

Coya Therapeutics advances COYA 303 for inflammatory diseases By Investing.com - Investing.com Australia

Jan 22, 2025

Jan 22, 2025

Coya Therapeutics (NASDAQ:COYA) Given “Buy” Rating at D. Boral Capital - Defense World

Jan 22, 2025

Jan 21, 2025

Coya Therapeutics' (COYA) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat

Jan 21, 2025

Jan 21, 2025

EXCLUSIVE: Coya Therapeutics Expands Its Pipeline With Combo Therapy For Inflammatory Diseases - AOL

Jan 21, 2025

Jan 21, 2025

Coya Therapeutics advances COYA 303 for inflammatory diseases - Investing.com India

Jan 21, 2025

Jan 21, 2025

Coya Therapeutics Unveils COYA 303: Novel GLP-1 Combination Therapy for Inflammatory Diseases - StockTitan

Jan 21, 2025

Jan 20, 2025

Coya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Up 10.2% in December - MarketBeat

Jan 20, 2025

Jan 15, 2025

Revolutionizing Success in the AI in Clinical Trials Market: - openPR

Jan 15, 2025

Jan 11, 2025

Geode Capital Management LLC Has $918,000 Stake in Coya Therapeutics, Inc. (NASDAQ:COYA) - Defense World

Jan 11, 2025

Jan 08, 2025

How to Take Advantage of moves in (COYA) - Stock Traders Daily

Jan 08, 2025

Dec 18, 2024

Coya Therapeutics (NASDAQ:COYA) Receives "Buy" Rating from D. Boral Capital - MarketBeat

Dec 18, 2024

Dec 18, 2024

Coya Therapeutics enrolls five in FTD study, eyes Phase 2 trial - Investing.com

Dec 18, 2024

Dec 18, 2024

Objective long/short (COYA) Report - Stock Traders Daily

Dec 18, 2024

Dec 16, 2024

Regulatory T-cells (Tregs) Therapies Market Key Players - openPR

Dec 16, 2024

Dec 10, 2024

Factors Influencing Global Regulatory T Cell Tregs Therapies - openPR

Dec 10, 2024

Dec 06, 2024

Exosome Therapeutics Market Applications in Neurological - openPR

Dec 06, 2024

Dec 04, 2024

Boral Capital initiates coverage on Coya Therapeutics with Buy rating By Investing.com - Investing.com Canada

Dec 04, 2024

Dec 04, 2024

Coya Therapeutics (NASDAQ:COYA) Now Covered by D. Boral Capital - MarketBeat

Dec 04, 2024

Dec 04, 2024

D. Boral Capital Initiates Coverage of Coya Therapeutics (COYA) with Buy Recommendation - MSN

Dec 04, 2024

Dec 02, 2024

INNOVATIONMAP EMAILS ARE AWESOME - InnovationMap

Dec 02, 2024

Nov 25, 2024

Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference - StockTitan

Nov 25, 2024

Nov 22, 2024

Alzheimer’s Disease Market Size to Reach US$ 6.3 Billion by 2034, Impelled by Advancements in Early Detection - IMARC Group

Nov 22, 2024

Nov 21, 2024

Coya Therapeutics files to sell 1.38M shares of common stock for holders - MSN

Nov 21, 2024

Nov 19, 2024

Coya Therapeutics sets sights on neurodegenerative trials in 2025 - Investing.com India

Nov 19, 2024

Nov 19, 2024

Coya Therapeutics Advances $700M ALS Program, Sets Key 2025 Clinical Milestones | COYA Stock News - StockTitan

Nov 19, 2024

Nov 16, 2024

Trend Tracker for (COYA) - Stock Traders Daily

Nov 16, 2024

Nov 15, 2024

Insider Buying: CFO David Snyder Acquires Shares of Coya Therape - GuruFocus.com

Nov 15, 2024